Medizone Home
×

FDA approves Mylan and Biocon’s Ogivri, the first biosimilar for trastuzumab in the USA

Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan’s Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab), co-developed with ...

Samsung Bioepis’ Herceptin biosimilar received final European approval

Samsung Bioepis Co., Ltd. announced the European Commission’s (EC) marketing authorization of Ontruzant, a biosimilar referencing Herceptin (trastuzumab), for the treatment of early breast cancer, metastatic ...

Samsung Bioepis first to receive EC approval for its third anti-TNF biosimilar

Samsung Bioepis Co., Ltd. last week announced the European Commission’s (EC) approval of Imraldi, a biosimilar referencing Humira (adalimumab). Imraldi is approved for the treatment of rheumatoid ...

Meet us at our booth at expopharm 2017 – 13th to 16th September

We are looking forward to welcoming you at our booth at expopharm 2017 - 13th to 16th September Medizone - Hall 5 - Booth A23 For more information visit expopharm exhibitor ...
Pages:«123456»